Antitargets and drug safety
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Language: | English |
| Published: |
Weinheim, Germany :
Wiley-VCH ,
c2015
|
| Series: | Methods and principles in medicinal chemistry
v. 66 |
| Subjects: |
Table of Contents:
- 1. Side effects of marketed drugs: the utility and pitfalls of pharmacovigilance
- 2. In silico prediction of drug side effects
- 3. Translational value of preclinical safety assessment: system organ class (SOC) representation of off-targets
- 4. Pathological conditions associated with the disturbance of the 5-HT system
- 5. Drug-induced liver injury: clinical and diagnostic aspects
- 6. Mechanistic safety biomarkers for drug-induced liver injury
- 7. In vitro models for the prediction of drug-induced liver injury in lead discovery
- 8. Transporters in the liver
- 9. Mechanistic modeling of drug-induced liver injury (DILI)
- 10. Functional cardiac safety evaluation of novel therapeutics
- 11. Safety aspects of the Cav1.2 channel
- 12. Cardiac sodium current (Nav1.5)
- 13. Circulating biomarkers for drug-induced cardiotoxicity: reverse translation from patients to nonclinical species
- 14. The mechanistic basis of hERG blockade and the proarrhythmic effects thereof
- 15. Introduction to kinase antitargets
- 16. Clinical and nonclinical adverse effects of kinase inhibitors
- 17. Cardiac side effects associated with kinase proteins and their signaling pathways
- 18. Case studies: selective inhibitors of protein kinases exploiting demure features
- 19. Torcetrapib and dalcetrapib safety: relevance of preclinical In vitro and In vivo models
- 20. Targets associated with drug-related suicidal ideation and behavior